

# landmARCC

Marking a turning point...

## Directors' Message

Welcome to the July 2012 issue of landmARCC!

Spring was an extremely productive time for the Canadian Centre for Applied Research in Cancer Control (ARCC). Hosting Canada's 1st Conference in Applied Research in Cancer Control was an honour and a significant achievement for ARCC and the cancer control community. Highlights and more information about the conference and can be found in this issue.

We are also pleased to announce that ARCC received the 2012 UBC Faculty of Medicine Distinguished Achievement Award for Excellence in Clinical and Applied Research for its outstanding contributions to

education, research and service. Selection was based on votes of Department Heads and School Directors.

ARCC has laid strong foundations for research and knowledge in health economics, services, policy and ethics in cancer control and we look forward to building on those foundations as we move into our fourth year.

Sincerely,  
Jeffrey & Stuart

ARCC co-directors  
Dr. Jeffrey Hoch (left)  
& Dr. Stuart Peacock  
(right)



## ARCC Conference 2012




Keynote Presenters:  
Dr. Michael Burgess, Diane McArthur and Dr. Mona Sabharwal

On May 28, 2012 ARCC hosted Canada's 1st Applied Research in Cancer Control Conference, an event that focused on health econom-

ics, services, policy and ethics in cancer control. This conference marked another significant milestone for ARCC. As the applied cancer research community continues to evolve and grow, the conference was an important venue to foster connections among academics, researchers, clinicians, students and policy makers. It is encouraging to see how engaged and motivated people are about applied research. ARCC will continue to be a resource centre for the cancer community.

It was a historic day with strong national leadership present. We had a total



Peter Goodhand,  
Outgoing President & CEO  
Canadian Cancer Society

of 135 registered participants, from 9 provinces and 80 oral and poster presentations. The turnout and cross country provincial representation provided for excellent networking and knowledge exchange opportunities.

We would like to thank the speakers for contributing significantly to the success of the ARCC Conference 2012. Conference keynote and plenary speakers included:

- Dr. Michael Burgess, Professor and Research Chair in Biomedical Ethics at the W. Maurice Young Centre for Applied Ethics in the Department of Medical Genetics at the University of British Columbia

- Dr. Andrew Coldman, Vice President of Population Oncology, BC Cancer Agency
- Dr. David Henry, President and CEO of the Institute for Clinical Evaluative Sciences (ICES)
- Ms. Diane McArthur, Assistant Deputy Minister and Executive Officer, Ontario Public Drug Programs for the Province of Ontario
- Dr. Mona Sabharwal, Inaugural Executive Director of the pan-Canadian Oncology Drug Review (pCODR)
- Dr. Carol Sawka, Vice President, Clinical Programs & Quality Initiatives and Co-Chair, Clinical Council, Cancer Care Ontario


*ARCC 2012 Conference continued on page 2*

### This issue of landmARCC

- Message from the Directors
- ARCC Conference 2012
- Upcoming events
- Recent publications
- PrePARE now available on Caner View Canada
- Did you know?
- Funding opportunities
- ARCC success stories
- Member spotlight
- Survey invitation
- Get Connected with ARCC
- Post-Doctoral Fellowship
- Mentorship opportunities

Want to share information in a future newsletter?  
If so, please contact [arcc@cancercare.on.ca](mailto:arcc@cancercare.on.ca)

ARCC 2012 Conference cont'd from page 1



Poster award winners with Dr. Jeffrey Hoch

Left Photo:  
Dr. Shawn Bugden,  
Associate Professor,  
Faculty of Pharmacy  
University of Manitoba

Right Photo:  
Audrey Wong,  
St. Michael's Hospital

**Congratulations ARCC Conference 2012 Poster Award Winners!**

- **Chemotherapy Waste: Implications for Value in Health**  
Dr. Shawn Bugden, Associate Professor, Faculty of Pharmacy, University of Manitoba
- **Adherence to Oncology Guidelines in Clinical Practice: A Quality Assurance Study in Early Stage Breast Cancer**  
Audrey Wong, St. Michael's Hospital

Conference presentations are now on our website at:

[www.cc-arcc.ca/events](http://www.cc-arcc.ca/events)

**Upcoming Events**

**ARCC Rounds**

Join us for the ARCC HTA Rounds with Mike Paulden

**When:** Friday, August 24, 2pm (EST)  
Wednesday, September 19, 2pm (EST)  
Wednesday, October 3, 2pm (EST)

**Where:** Online meeting via lync

For more information about this series: [click here](#)

To see previous slides: [click here](#)

For more information and to register for the meeting contact: [click here](#)

**UICC 2012 World Cancer Congress**

Connecting for Global Impact August 27-29, 2012  
Montréal Convention Center, Montréal, Québec  
[www.worldcancercongress.org](http://www.worldcancercongress.org)

**Health Technology Assessment for Decision Makers**

An intensive course on pragmatic HTA tools for decision makers, industry representatives and researchers  
July 25- 27, 2012 University of Toronto  
For more information: [click here](#)

**Priorities 2012 September 16 - 19, 2012**

Westin Bayshore Vancouver BC  
For more information: [click here](#)

**American Society of Clinical Oncology (ASCO) Quality Care**

Symposium November 30 - December 1, 2012  
Manchester Grand Hyatt, San Diego, CA  
For more information: [click here](#)



**SAVE THE DATE!**  
**May 27, 2013**  
**ARCC Conference 2013**  
**Vancouver, British Columbia**

**Recent Publications**

- **Bansback N, Tsuchiya A, Brazier J, Anis A.** Canadian Valuation of EQ-5D Health States: Preliminary Value Set and Considerations for Future Valuation Studies. *PLoS ONE* 2012; 7(2): e31115.
- **Burnett H, Regier DA, Feldman B, Miller FA, Ungar W.** Parents' preferences for drug treatment in juvenile idiopathic arthritis: a discrete choice experiment. *Arthritis Care & Research* doi 10.1002/acr.21698
- **Cromwell I, van der Hoek K, Malfair Taylor SC, Melosky B, Peacock S.** Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: A real-world cost-effectiveness analysis. *Lung Cancer*. 2012 Jun; 76(3):472-7.
- **Hannouf M, Sehgal C, Cao J, Mocanu J, Winquist E, Zaric G, Zaric S.** Cost-Effectiveness of Adding Cetuximab to Platinum-Based Chemotherapy for First-Line Treatment of Recurrent or Metastatic Head and Neck Cancer Department of Epidemiology *PLoS ONE: Research Article*, published 20 Jun 2012
- **Hedden L, Kennecke H, Villa D, Johnston K, Speers C, Kovacic L, Renouf DJ, Peacock S.** Incremental cost-effectiveness of the pre- and post-bevacizumab eras of metastatic colorectal cancer therapy in British Columbia, Canada. *Eur J Cancer*. 2012 Feb 9.
- **Hedden L, O'Reilly S, Lohrisch C, Chia S, Speers C, Kovacic L, Taylor S, Peacock S.** Assessing the real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu positive breast cancer. *Oncologist*. 2012; 17(2):164-71.
- **Mittmann N, Evans WK, Rocchi A, Longo CJ, Au HJ, Husereau D, Leighl NB, Isogai PK, Krahn MD, Peacock S, Marshall D, Coyle D, Malfair TSC, Jacobs P, Oh PI.** Guidelines for Health Technologies: specific guidance for oncology products in Canada. *Value in Health*. (March 2012).
- **Mittmann N, Isogai PK, Connors JM, Rebeira M, Cheung MC.** Economic analysis of alemtuzumab (MabCampath) in fludarabine-refractory chronic lymphocytic leukemia. *The Open Pharmacoeconomics and Health Economics Journal*. 2012; 4: 18-25.
- **Regier DA, Ramsey S.** 2012. Economic analyses alongside cancer clinical trials. In, Crowley J, Ankerst DP (eds), *Handbook of statistics in clinical oncology*. 3rd Ed. Chapman & Hall/CRC.
- **Richardson J, Peacock S, Hawthorne G, Iezzi A, Elsworth G, Day N.** Construction of the descriptive system for the assessment of quality of life AQoL-6D utility instrument. *Health and Quality of Life Outcomes* 2012, 10:38 (17 April 2012). [pubmed link](#)
- **Sung L, Alibhai SH, Ethier MC, Cheng S, Teuffel O, Fisman D, Regier DA.** Discrete choice experiment produced estimates of acceptable risks of therapeutic options in cancer patients with febrile neutropenia. *Journal of Clinical Epidemiology*. 2012 Jun;65(6):627-34. [pubmed link](#)
- **Ubel PA, Berry SR, Nadler E, Bell CM, Kozminski MA, Palmer JA, Evans WK, Strevel EL, Neumann PJ.** In A Survey, Marked Inconsistency In How Oncologists Judged Value Of High-Cost Cancer Drugs In Relation To Gains In Survival. *Health Aff* April 2012 31:709-717.
- **Yong JHE, Beca J, McGowan T, Bremner KE, Warde W, Hoch JS.** Cost-effectiveness of Intensity-modulated Radiotherapy in Prostate Cancer, *Clinical Oncology* (2012), doi:10.1016/j.clon.2012.05.004

**Do you have a publication you want to share in the next Newsletter? Let us know!**

## PrePARE is now available on Cancer View Canada!

The **Pre**paring **P**articipants for **A**llocating **R**esources **E**quitably (PrePARE) tutorial is an interactive training tool designed to help support public discussion and expert deliberations on how health-care funding recommendations are made and for what drugs, programs, and treatments should receive public funding in Canada's health-care system. The tutorial is developed by the Cancer Guidelines Advisory Group of the *Canadian Partnership Against Cancer* ([www.partnershipagainstcancer.ca](http://www.partnershipagainstcancer.ca)) in partnership with the Canadian Centre for Applied Research in Cancer Control ([www.cc-arcc.ca](http://www.cc-arcc.ca)). ARCC also contributed funding to support the evaluation of the PrePARE tool.

The overarching objectives of PrePARE are to make priority-setting decisions more understandable and therefore more acceptable to cancer control stakeholders, and to help individuals be constructive contributors to debates that affect how Canadians invest the increasingly limited amount of dollars allocated for health care.

To access the PrePARE online tutorial, you must first register with Cancer View Canada, which is the CPAC portal. Follow the steps under Registration, below. If you already have a [cancerview.ca](http://cancerview.ca) account, please follow the instructions under Login to e-Learning, below.

### Registration

- Access <http://elearning.cancerview.ca/registration>
- Complete the required information and set a password.

### Login to e-Learning

- Access <http://elearning.cancerview.ca/login>
- Enter username and password.

For further information, questions, or to explore collaboration based on the PrePARE tool, please contact:

Louise Zitzelsberger at [louise.zitzelsberger@partnershipagainstcancer.ca](mailto:louise.zitzelsberger@partnershipagainstcancer.ca)

## Did you know?

Proposed Changes to CIHR's Open Suite of Programs and Enhancements to the Peer Review Process. For more information see [here](#)

### Funding Opportunities

**A Research and Knowledge Network on Genetic Health Services and Policy call for applications for MSc/PhD Training Fellowships**

For more information [click here](#)

**Ontario Institute for Cancer Research (OICR) High Impact Clinical Trials Program 2012-2013 Request for Proposals**

For more information [click here](#)

**Mitacs Globalink Call: Open to Faculty in All Disciplines**

- Deadline July 31, 2012

For further information about the Mitacs Globalink program and how to apply, [click here](#)

**Innovation Grants** competition is now available via the Canadian Cancer Society Research Institute (CCSRI)

Abstract registration must be completed by August 15 in order to submit a **full application**.

## ARCC Success Stories

### Congratulations!

- **Dr. Christopher Longo** for winning the Emerald Literati Network 2012 Awards for Excellence for his article entitled "Encouraging pharmaceutical innovation to meet the needs of both developed and developing countries" published in *International Journal of Development Issues*.
- **Dr. Gregory Zaric** and news of his CIHR grant [click here](#)
- **Dr. Dean Regier** on being awarded the ISPOR Research Presentations Podium Award and being selected as best new investigator podium presentation at the ISPOR 17th Annual International Meeting, in Washington, DC.
- **Dr. Sonya Cressman** for receiving the Betty Rice Award for her health economics work on the pan-Canadian lung cancer screening trial.
- **Corneliu Bolbocean** for winning a CADTH student travel award.
- **Syed Rahman** for winning a travel award from the BC Cancer Agency Jambor Knowledge Fund to attend the UICC 2012 World Cancer Congress.

Do you have a success story you want in the next newsletter?  
Share with us!

## Member Spotlight

Dr. Dean Regier recently joined ARCC as Senior Health Economist. Dean has a background in economics, health economics and public health. He has held posts as an Assistant Member at the Fred Hutchinson Cancer Research Center and an Assistant Professor at the University of Washington, Seattle.



### 1. Tell us a bit about yourself, Dean

My academic work has concentrated on econometric methods for preference elicitation and cost effectiveness analysis. With stops in Aberdeen, Scotland (University of Aberdeen), Oxford, England (University of Oxford), Toronto, Canada (SickKids Hospital), Seattle, Washington (University of Washington), my trajectory to Vancouver and ARCC has not been straightforward. The process, however, has been exhilarating, and I am 'chuffed' (as they say in the UK) to have landed in Vancouver working within ARCC.

### 2. What are your plans with ARCC?

I am interested in understanding and quantifying individuals' decisions and well-being surrounding personalized medicine in cancer. I am especially interested in how such research can be used to understand patient decision-making and inform Canadian health policy. Given its pan-Canadian network of investigators, coupled with co-location with world-leading research centres, ARCC provides the perfect platform for my academic pursuits.

### 3. What is your favorite hobby?

I run. Notwithstanding the health benefit, (and sometimes risks, including rolling my ankle at least once a year), I run to think. I often find some of my best (and more outlandish) ideas come at around the 45 minute mark.

---

## Invitation to participate in survey about cancer drug funding decisions

The decision to list cancer drugs on the provincial formulary is complex, since clinical, economic, and ethical factors must be considered. Economic evidence should play an important role in the decision process. But exactly what role does economics play? We invite you to participate in this survey and share your perceptions on this important topic. It will take 15-20 minutes and you can qualify for a cash prize. [Click here](#)

This survey is a part of a study led by Dr. Dominika Wranik, Dr. Jeffrey Hoch, and Dr. Adrian Levy, in collaboration with Dr. Stirling Bryan and Dr. Mark Dobrow. The study is partially funded by ARCC and CIHR. The goal is to identify flaws in the process of using economic evidence in cancer drug funding decisions, and to address those flaws with the development of a procedural framework.

## Post-Doctoral Fellowship in Palliative Care, Cancer, and Health System Innovation McMaster University & Juravinski Cancer Centre, Hamilton, Ontario

Applications are invited for a 1-2 year post-doctoral fellowship in the areas of palliative care, cancer, and health system innovation; successful candidates should have completed a PhD in a related and relevant area. We welcome candidates from a variety of backgrounds, such as health services research, epidemiology, public health, gerontology and aging, etc. The primary objective of this fellowship is to support the academic development of an emerging researcher interested in similar areas of research by providing additional training, research opportunities, and mentorship. The fellow will be exposed to projects in health services research, health system innovation, program evaluation, and policy-relevant applied research, mostly related to palliative care and cancer care within the broad health system, including the home and community setting.

Fellows will work under the supervision of Dr. Hsien Seow. ([click here](#)) They will also have opportunities to work with health services researchers within the Department of Oncology, McMaster University. The position is available September 1, 2012, but could be negotiated for later start date. Applications will be accepted until the position is filled. Please send letters indicating qualifications and interests along with a curriculum vitae and 3 suggested references to the attention of: Wanda Oldfield, [click here](#)

## ARCC Get Connected

The new website feature to help you connect with other researchers! You can create an online profile, search other users and connect!

Joining the Get Connected is easy...

### ARCC Get Connected Instructions:

- 1) Go to [www.cc-arcc.ca](http://www.cc-arcc.ca)
- 2) Click on 'sign up' on top right hand corner.
- 3) Fill out of the registration form and ensure all required fields are entered.
- 4) You will receive an automatic response letting you know it has been submitted.
- 5) Once approval email is received from ARCC click on the log in located on the top right hand corner of the ARCC homepage.
- 6) Once logged in you can view, edit or search other members by clicking my profile.

## Mentorship Program

Want to be a mentor or protégé?

If so please contact [arcc@cancercare.on.ca](mailto:arcc@cancercare.on.ca)